Resolution of primary hepatic marginal zone lymphoma in a hepatitis C virus-infected patient treated with a direct-acting antiviral.

HCV infection antiviral therapy liver lymphoma marginal zone lymhoma sofosbuvir

Journal

Oxford medical case reports
ISSN: 2053-8855
Titre abrégé: Oxf Med Case Reports
Pays: England
ID NLM: 101642070

Informations de publication

Date de publication:
May 2021
Historique:
received: 19 10 2020
revised: 05 02 2021
accepted: 18 02 2021
entrez: 31 5 2021
pubmed: 1 6 2021
medline: 1 6 2021
Statut: epublish

Résumé

The favorable impact of antiviral therapy on low-grade hepatitis C virus (HCV)-related non-Hodgkin lymphoma manifesting as marginal zone lymphoma (MZL) has been reported in some clinical studies. However, primary HCV-related marginal zone lymphomas (MZLs) confined to the liver have not been described in the literature nor have the resolution of liver lymphoma through anti-HCV eradication treatment. The authors report a genotype 1b HCV-positive patient with chronic hepatitis who exhibited lesions involving both hepatic lobes resembling hepatocellular carcinoma. Liver biopsy revealed an MZL of the liver. Antiviral treatment using sofosbuvir associated with simeprevir as unique treatment was started and resulted in complete haematological response. In HCV-related MZL isolated to the liver, antiviral treatment has led to the eradication of viral infection and a complete haematological response. Antiviral therapy should be considered as a first-line treatment for HCV-related primary MZLs of the liver.

Identifiants

pubmed: 34055359
doi: 10.1093/omcr/omab022
pii: omab022
pmc: PMC8143661
doi:

Types de publication

Case Reports

Langues

eng

Pagination

omab022

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Références

World J Hepatol. 2016 Jan 18;8(2):107-16
pubmed: 26807206
Maedica (Bucur). 2016 Sep;11(3):250-254
pubmed: 28694862
N Engl J Med. 2002 Jul 11;347(2):89-94
pubmed: 12110736
World J Gastroenterol. 2010 Dec 21;16(47):6016-9
pubmed: 21157979
Hepatology. 2011 Oct;54(4):1433-44
pubmed: 21898493
Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8
pubmed: 18387498
J Viral Hepat. 2016 Jul;23(7):536-44
pubmed: 26924533
Semin Hematol. 2019 Jan;56(1):30-36
pubmed: 30573042

Auteurs

Adriano Pellicelli (A)

Liver Unit, Department of Liver Transplant, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.

Valerio Giannelli (V)

Liver Unit, Department of Liver Transplant, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.

Valerio Zoli (V)

Hematology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.

Giovanni Regine (G)

Department of Radiology, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.

Andrea Cortese (A)

Department of Radiology, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.

Giuseppe M Ettorre (GM)

Division of General Surgery and Liver Transplantation, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.

Enrico Carmenini (E)

Liver Unit, Department of Liver Transplant, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.

Valeria Pellicelli (V)

Internal Medicine, Azienda Ospedaliera Sant'Andrea Università degli Studi "La Sapienza", Rome, Italy.

Luigi Rigacci (L)

Hematology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.

Classifications MeSH